-
Tesaro Inc
-
Sector
Health Care
-
Industry
Biotechnology
-
Company web
Link
-
Employees
Full Time Employees: 446
-
Executives
- David Mott
- Mary Hedley
- Leon Moulder
- Timothy Pearson
- Jeffrey Hanke
- Joseph Farmer
- Grant Bogle
- Martin Huber
- Lawrence Alleva
- James Armitage
-
Company address
- 1000 Winter Street, Suite 3300
- Waltham, MA 02451
- United States of America
- 1-339-970-0900
-
Investor Relation Site
Link
Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. The company is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in pre-clinical research stage targeting lymphocyte-activation gene-3. It has license and collaboration agreements with AnaptysBio, Inc.; and The University of Texas MD Anderson Cancer Center, as well as with Janssen Biotech, Inc., Zai Lab (Shanghai) Co., Ltd, OPKO Health, Inc. The company also has collaboration agreements with Evotec AG and OncoQuest Inc. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Tesaro Inc: Slide deck